COH ASX: Cochlear lifts guidance despite Moderna hearing vaccine threat
The hearing implant device maker’s shares rose more than 3 per cent after the company lifted its earnings forecasts.
Stay updated with breaking news from Saul Hadassin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The hearing implant device maker’s shares rose more than 3 per cent after the company lifted its earnings forecasts.
The hearing device maker, which grew profits but saw a margin squeeze, is forecasting a boost this year.
Blood Money | After Paul Perreault grew CSL revenue by $US5 billion and profit by $US1 billion, the pressure is on new CEO Paul McKenzie to keep up the growth.
Blood Money | Under Paul Perreault, CSL became one of the biggest companies in the country, but even in 2010 its Melbourne offices still looked like something out of the 1960s.
ACL’s audacious hostile takeover bid for larger rival Healius is unlikely to succeed on account of price, and dim prospects for ACCC approval.